Skip to main content
SpringerLink
Log in

Population Pharmacokinetic/Pharmacodynamic Modelling of Dipeptidyl Peptidase IV Inhibitors

  • Commentary
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–57.

    Article  CAS  PubMed  Google Scholar 

  2. Naslund E, Bogefors J, Skogar S, Gryback P, Jacobsson H, Holst JJ, et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol. 1999;277(3 Pt 2):R910–6.

    CAS  PubMed  Google Scholar 

  3. Graham G, Gupta S, Aarons L. Determination of an optimal dosage regimen using a Bayesian decision analysis of efficacy and adverse effect data. J Pharmacokinet Pharmacodyn. 2002;29(1):67–88.

    Article  CAS  PubMed  Google Scholar 

  4. Gibbs JP, Fredrickson J, Barbee T, Correa I, Smith B, Lin SL, et al. Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. J Clin Pharmacol. 2012;52(10):1494–505.

    Article  CAS  PubMed  Google Scholar 

  5. Kim BH, Kim SE, Kang D, Lim KS, Kim JR, Jang IJ, et al. Pharmacokinetic-pharmacodynamic modelling of biomarker response to sitagliptin in healthy volunteers. Basic Clin Pharmacol Toxicol. 2013;113(2):113–25.

    Article  CAS  PubMed  Google Scholar 

  6. Velez de Mendizabal N, Strother RM, Farag SS, Broxmeyer HE, Messina-Graham S, Chitnis SD, et al. Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation. Clin Pharmacokinet. 2014;53(3):247–59.

    Article  CAS  PubMed  Google Scholar 

  7. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008;325(1):175–82.

    Article  CAS  PubMed  Google Scholar 

  8. Retlich S, Duval V, Graefe-Mody U, Jaehde U, Staab A. Impact of target-mediated drug disposition on linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. J Clin Pharmacol. 2010;50(8):873–85.

    Article  CAS  PubMed  Google Scholar 

  9. Retlich S, Duval V, Graefe-Mody U, Friedrich C, Patel S, Jaehde U, et al. Population pharmacokinetics and pharmacodynamics of linagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2015. doi:10.1007/s40262-014-0232-4 (Epub 31 Jan 2015).

  10. Tadayasu Y, Sarashina A, Tsuda Y, Tatami S, Friedrich C, Retlich S, et al. Population pharmacokinetic/pharmacodynamic analysis of the DPP-4 inhibitor linagliptin in Japanese patients with type 2 diabetes mellitus. J Pharm Pharm Sci. 2013;16(5):708–21.

    PubMed  Google Scholar 

  11. Landersdorfer CB, He YL, Jusko WJ. Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. Br J Clin Pharmacol. 2012;73(3):391–401.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Landersdorfer CB, He YL, Jusko WJ. Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. Br J Clin Pharmacol. 2012;73(3):373–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Agrawal R, Bahare RS, Jain P, Dikshit SN, Ganguly S. Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin. Mini Rev Med Chem. 2012;12(13):1345–58.

    CAS  PubMed  Google Scholar 

  14. Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res. 2006;3(3):159–65.

    Article  PubMed  Google Scholar 

  15. Landersdorfer CB, Jusko WJ. Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. Clin Pharmacokinet. 2008;47(7):417–48.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Australian National Health and Medical Research Council (NHMRC; Career Development Fellowship Number 1062509 to Cornelia B. Landersdorfer).

Disclosures

Cornelia B. Landersdorfer has no conflicts of interest that might be relevant to the contents of this commentary.

Author information

Authors and Affiliations

  1. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, VIC, 3052, Australia

    Cornelia B. Landersdorfer

  2. School of Pharmacy and Pharmaceutical Sciences, SUNY Buffalo, Buffalo, NY, USA

    Cornelia B. Landersdorfer

Authors
  1. Cornelia B. Landersdorfer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cornelia B. Landersdorfer.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Landersdorfer, C.B. Population Pharmacokinetic/Pharmacodynamic Modelling of Dipeptidyl Peptidase IV Inhibitors. Clin Pharmacokinet 54, 673–675 (2015). https://doi.org/10.1007/s40262-015-0279-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-015-0279-x

Keywords

Search

Navigation